Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice

Zhang, Xiao Yun; Qiao, Hui; Ni, Jinfeng; Shi, Yanbin; Yin, Qiang

doi:10.1016/j.ejps.2013.04.020

Cited by 51 publications

(27 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in the table, while the system showed minimal changes in terms of S z , PDI, or EE, and thereby, exceptional stability upon storage at 4°C, it showed marginal changes in S z , PDI, and EE upon storage at 22°C. This behavior of the system was expected, as upon storage, lipid nanoparticles generally show an increase in size and decrease in encapsulation (33,34). Nevertheless, the system remained well within the acceptable ranges of all parameters at 22°C, showing good stability upon storage at room temperature as well.…”

Section: Physical Stability Studysupporting

confidence: 58%

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

et al. 2015

View full text Add to dashboard Cite

Abstract. Imatinib (IMT), an anticancer agent, inhibits receptor tyrosine kinases and is characterized by poor aqueous solubility, extensive first-pass metabolism, and rapid clearance. The aims of the current study are to prepare imatinib-loaded solid lipid nanoparticles (IMT-SLN) and study the effects of associated formulation variables on particle size and drug encapsulation on IMT-SLN using an experimental design. IMT-SLN was optimized by use of a Bcombo^approach involving Plackett-Burman design (PBD) and Box-Behnken design (BBD). PBD screening resulted in the determination of organic-toaqueous phase ratio (O/A), drug-to-lipid ratio (D/L), and amount of Tween® 20 (Tw20) as three significant variables for particle size (S z ), drug loading (DL), and encapsulation efficiency (EE) of IMT-SLN, which were used for optimization by BBD, yielding an optimized criteria of O/A=0.04, D/L=0.03, and Tw20=2.50%w/v. The optimized IMT-SLN exhibited monodispersed particles with a size range of 69.0±0.9 nm, ζ-potential of −24.2±1.2 mV, and DL and EE of 2.9±0.1 and 97.6±0.1%w/w, respectively. Results of in vitro release study showed a sustained release pattern, presumably by diffusion and erosion, with a higher release rate at pH 5.0, compared to pH 7.4. In conclusion, use of the combo experimental design approach enabled clear understanding of the effects of various formulation variables on IMT-SLN and aided in the preparation of a system which exhibited desirable physicochemical and release characteristics.

show abstract

Section: Physical Stability Studysupporting

confidence: 58%

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

et al. 2015

View full text Add to dashboard Cite

show abstract

“…19 Previous studies have also proven that NLCs can prolong exposure to the tumor cells, enhance the permeability and retention effect, and increase the therapeutic effect. 20,21 In our previous study, 8 TQ has been successfully encapsulated in NLC (hereinafter referred to as TQNLC), with excellent physiochemical properties such as high encapsulation efficiency (EE), high DL capacity, particle diameter less than 100 nm, and good stability up to 2 years. In vitro studies also have proven that TQNLC exhibited antiproliferative activity toward breast cancer cell lines (MDA-MB-231 and MCF 7) and cervical cancer cell lines (HeLa and SiHa).…”

mentioning

confidence: 99%

Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice

Ong

Yazan

et al. 2016

IJN

View full text Add to dashboard Cite

“…24,[31][32][33] However, in this project the effective dose was decreased to 25 mg/kg every 2 days in the 4T1-bearing nude-mouse model. Also, the administration method was intraperitoneal rather than IV injection, which was because the volume of the NPs was too large to use IV injections.…”

Section: In Vivo Antitumor Efficacy Of Isl-irgd Npsmentioning

confidence: 99%

“…24,25 Herein, iRGD-modified lipid-polymer NPs were used to encapsulate ISL (structure of NPs in Figure 1A). The basic characteristics, pharmacological efficacy, and targeting ability of the novel NPs were studied and are evaluated in this paper.…”

mentioning

confidence: 99%

iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability

Gao

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

Isoliquiritigenin (ISL), a natural anti-breast cancer dietary compound, has poor delivery characteristics and low bioavailability. In order to promote the therapeutic outcome of ISL, a tumor-targeting lipid–polymer hybrid nanoparticle (NP) system modified by tumor-homing iRGD peptides has been developed. The hybrid NPs were prepared by a modified single-step nanoprecipitation method to encapsulate ISL. iRGD peptides were anchored on the surface by a postinsertion method (ISL-iRGD NPs). The stable lipid–polymer structure of ISL-iRGD NPs, with high encapsulation and loading efficiency, was confirmed. Compared to free ISL and non-iRGD-modified counterparts, ISL-iRGD NPs showed higher cytotoxicity and cell apoptosis against the different type of breast cancer cells. This was attributable to higher cellular accumulation mediated by the iRGD-integrin recognition and the nanoscale effect. More importantly, based on the active tumor-tissue accumulation by iRGD peptides and the prolonged in vivo circulation by the stealth nanostructure, ISL-iRGD NPs displayed higher tumor-growth inhibition efficiency in 4T1-bearing breast-tumor mouse models. Therefore, the constructed iRGD modified lipid–polymer hybrid NPs would provide a promising drug-delivery strategy to improve ISL in anti-breast cancer efficacy.

show abstract

Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice

Cited by 51 publications

References 52 publications

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice

iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability

Contact Info

Product

Resources

About

Preparation of isoliquiritigenin-loaded nanostructured lipid carrier and the in vivo evaluation in tumor-bearing mice

Cited by 51 publications

References 52 publications

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

Effects of Formulation Variables on the Particle Size and Drug Encapsulation of Imatinib-Loaded Solid Lipid Nanoparticles

Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice

iRGD-modified lipid&ndash;polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability

Contact Info

Product

Resources

About

iRGD-modified lipid–polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability